Attacking Tumors at the Source

Our technology provides a new opportunity to “drug the undruggable”. We target specific protein-protein interactions, which when disrupted can lead to a “pro-cell death” fate or modulated immune response in targeted cells.

View Our Platform

Enabling Treatments Aimed at Dysregulated PPIs

Our lead candidate, ST101, is a cell-penetrating peptide antagonist of C/EBPβ designed to target various solid tumors (including breast cancer, melanoma, prostate cancer, GBM, lung cancer, and AML) and hematologic malignancies.

In July 2020, we initiated the first clinical trial for ST101, which has also been granted Orphan Drug Designation for the treatment of glioma and AML by the U.S. FDA.

More About ST101

Latest News

Sapience Therapeutics Appoints J. Andrew Sanford to Its Board of Directors

Sapience Therapeutics Renews Drug Discovery Pact with the University of Bath

Sapience Therapeutics Completes $14 million Preferred Stock Financing

Sapience Therapeutics Awarded SBIR Phase I Grant from National Cancer Institute

Sapience Therapeutics Announces First Patient Dosed with ST101 in Phase 1/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors

Sapience Therapeutics to Present Data on its Two Lead Programs at 2020 AACR Virtual Annual Meeting II

Sapience Therapeutics Announces FDA Acceptance of IND Application for ST101 in Advanced Cancer Indications

Sapience Therapeutics Receives United Kingdom Authorization to Initiate a Phase 1/2 Trial of Lead Candidate ST101 in Advanced Cancer Indications

Sapience Therapeutics to Present at Biotech Showcase 2020

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today